MS patients treated with interferon-beta showed increased percentages of iNKT cells among peripheral blood mononuclear cells and an improved cytokine secretion in response to α-GalCer [15], while patients treated with natalizumab displayed lower levels of iNKT cells producing IL-17, TNF and IFN-gamma compared to patients on interferon-beta or glatiramer acetate [9]. Here, IL17A is linked to myeloid sarcoma.